201 related articles for article (PubMed ID: 35659376)
1. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.
Minotti G; Menna P; Camilli M; Salvatorelli E; Levi R
Adv Pharmacol; 2022; 94():365-409. PubMed ID: 35659376
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
3. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.
Sheppard CE; Anwar M
J Oncol Pharm Pract; 2019 Jul; 25(5):1231-1234. PubMed ID: 29945530
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
Minotti G
J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
Minotti G; Menna P; Calabrese V; Greco C; Armento G; Annibali O; Marchesi F; Salvatorelli E; Reggiardo G
J Pharmacol Exp Ther; 2019 Aug; 370(2):197-205. PubMed ID: 31101682
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.
Menna P; Calabrese V; Armento G; Annibali O; Greco C; Salvatorelli E; Marchesi F; Reggiardo G; Minotti G
J Pharmacol Exp Ther; 2018 Jul; 366(1):158-168. PubMed ID: 29720563
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
10. The concomitant management of cancer therapy and cardiac therapy.
Salvatorelli E; Menna P; Cantalupo E; Chello M; Covino E; Wolf FI; Minotti G
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2727-37. PubMed ID: 25596534
[TBL] [Abstract][Full Text] [Related]
11. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
Martín-Garcia A; López-Fernández T; Mitroi C; Chaparro-Muñoz M; Moliner P; Martin-Garcia AC; Martinez-Monzonis A; Castro A; Lopez-Sendon JL; Sanchez PL
ESC Heart Fail; 2020 Apr; 7(2):763-767. PubMed ID: 32022485
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
Robinson EL; Azodi M; Heymans S; Heggermont W
Curr Heart Fail Rep; 2020 Dec; 17(6):357-364. PubMed ID: 32964378
[TBL] [Abstract][Full Text] [Related]
14. [Sacubitril/valsartan in oncologic patients with cardiotoxicity: another weapon in our pharmacological armory?].
Camilli M; Bisceglia I; Canale ML; Di Tano G; Oliva F; Gabrielli D; Gulizia MM; Colivicchi F
G Ital Cardiol (Rome); 2022 Apr; 23(4):278-285. PubMed ID: 35343479
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
Tantawy M; Pamittan FG; Singh S; Gong Y
Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
[TBL] [Abstract][Full Text] [Related]
16. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
Maradia K; Guglin M
Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
[TBL] [Abstract][Full Text] [Related]
19. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
Pantazi D; Tselepis AD
Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
